Loading…
← CockpitCompetitor Analysis › ARDT Ardent Health, Inc.Open in the cockpit ↗

Ardent Health, Inc.ARDTCompetitor analysis, valuation and peers

United States · USD·Health Care›Hospital/Nursing Management

Owns and operates acute care hospitals and outpatient facilities across several urban and suburban US markets.

Momentum leader 96
Mkt cap
$2.03B
US dollars, full cap
Free float
16%
of shares outstanding
$/day
$17.9M
20-day average traded
Fwd P/E
11.9×
forward earnings
ROIC−WACC
+0.5 pp
WACC 6.7%
Hurdle
-10 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · USD$14.40
1D-18.9%
1W-20.8%
1M+18.8%
3M+37.4%
6M+52.4%
YTD+63.1%
1Y+73.9%
ATR %7.2%
Beta0.28
52w lowhigh22.5% off high

What Ardent Health does

Owns and operates acute care hospitals and outpatient facilities across several urban and suburban US markets.

Is paid by health insurers, Medicare and Medicaid for each patient treated, with commercially insured patients paying best, so insurance mix and admission volume drive results. Equity Group Investments, the Zell family's investment firm, remains its controlling shareholder after the 2024 listing.

Products and services

  • Acute care hospitals
  • Outpatient services
  • Physician network (Ardent Medical Group)

Customers

  • Patients
  • Health insurers
  • Employer/physician groups

Where it sits in the supply chain

  • Healthcare services
  • Acute care hospital operator
  • Hospital and outpatient network

What could go right

  • Local market consolidation
  • Aging population demand

What could go wrong

  • Labor cost inflation
  • Reimbursement/payer mix risk

Moat: none (scale, regulatory licence). Local market share and certificate-of-need licensing help, but hospital care is capital- and labor-intensive with thin differentiation.

Headquarters: Nashville, Tennessee, United States · Founded: 2001 · Employees: 25,200

Named competitors

Ardent Health at a glance

Size Ardent Health (ARDT) is a United States Health Care company (Hospital/Nursing Management) with a market value of $2.03B, the 1765th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.40 on 18 Nov 2026.

Performance Over six months the shares gained 52.4%, against -0.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 2.0% over the last twelve months (peer median +8.7%); the operating margin is 5.2% (peer median 10.8%).

Valuation It trades at 11.9× forward earnings against a peer median of 35.5× (cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.5 points above its cost of capital (6.7% WACC).

Short interest Short interest is 2.5% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026ARDT 156Peer median 100
Six months, rebased to 100: Ardent Health against the median of its 20 peers (local-currency closes).

Ardent Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$6.45B$6.32B$5.97B$5.41B$5.13B
Revenue growth—+6%+10%+5%—
Gross profit$994M$973M$902M$668M$665M
EBITDA$503M$481M$552M$357M$338M
Net income$146M$136M$210M$53.9M$189M
Free cash flow$282M$256M$128M$84.3M-$189M
Capital expenditure$200M$212M$188M$137M$151M
Total debt$2.27B$2.32B$2.28B$2.40B$2.39B

Quarterly statements and history in the cockpit →

Ardent Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%BKDEXE301267600763SIA000516AEVS301293SPINHCCVSGKIMSSGRYYATHARTHPARKHOSPSRHKJLHLCBAVARDT6-month return →1-month return →
Up and to the right = strong over both horizons. Ardent Health is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×BKDEXE301267600763SIAAEVSRAINBOW301293BSLKIMSSGRYYATHARTHPARKHOSPSCBAVARDTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ardent Health is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%BKDEXE301267600763SIA000516AEVSRAINBOWSPINHCBSLCVSGSGRYPARKHOSPSCBAVARDTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ardent Health is the large dot.

Ardent Health competitors and peer comparison

Head to head with its named competitors (ARDT vs HCA vs CYH vs THC)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ardent Health ARDT$2.03B+52%+2%5%11.9×-1.7%
HCA Healthcare HCA$99.5B+20%+6%15%15.6×3.1%
Community Health Systems CYHn/a-34%n/an/an/an/a
Tenet Healthcare THC$21.6B+45%+6%17%13.4×-1.4%
Universal Health Services UHS$10.7B+13%+8%11%8.3×-1.8%

How Ardent Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ardent Health against its 20 peers (data as of 18 Nov 2026)
MeasureARDTPeer medianRank in peer set
1-month return+18.8%+1.7%2nd highest of 21
6-month return+52.4%-0.6%2nd highest of 21
Distance from 52-week high-22.5%-16.9%8th lowest of 21
Revenue growth (TTM)+2.0%+8.7%5th lowest of 21
Operating margin5.2%10.8%5th lowest of 21
Forward P/E11.9×35.5×cheapest of 19
Growth the price implies (Req g, 7 yrs)-1.7%12.7%2nd least demanding of 16
Growth delivered (Del g)+8.7%+10.2%7th lowest of 16
Hurdle (Req g minus delivered)-10.4 pp+3.4 pp2nd least demanding of 16
ROIC minus cost of capital+0.5 pp-2.7 pp8th highest of 21
EV / EBITDA7.8×14.9×cheapest of 14
Net debt / EBITDA3.0×2.2×8th most indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ardent Health ARDTUnited States$2.03B+52%+2%5%11.9×-1.7%+8.7%
Brookdale Senior Living BKDUnited States$2.06B-36%-8%6%482.6×19.3%-1.4%
Extendicare EXE.TOCanada$1.91B-16%+36%9%19.3×10.8%+8.5%
Huaxia Eye Hospital 301267.SZChina$1.78B-18%+2%15%23.5×2.1%+10.4%
Topchoice Medical 600763.SSChina$2.33B-12%+7%26%24.8×12.4%+6.9%
Sienna Senior Living SIA.TOCanada$1.58B-8%+15%10%40.9×18.9%+8.6%
Xi'an International Medical Investment 000516.SZChina$1.46B-2%-1%-2%n/a12.7%+20.6%
Aevis Victoria AEVS.SWSwitzerland$1.43B+8%+15%-6%106.8×26.5%+10.2%
Rainbow Childrens Medicare RAINBOW.NSIndia$1.37B-7%+23%22%40.4×30.7%+21.2%
Sanbo Hospital Management 301293.SZChina$1.35B-29%+17%6%135.5×n/an/a
Spire Healthcare SPI.LUnited Kingdom$1.31B+11%+2%8%25.1×10.0%+11.4%
National HealthCare NHCUnited States$3.16B+1%+6%0%n/a6.4%+9.7%
Raffles Medical BSL.SISingapore$1.23B-13%-3%11%27.1×-2.7%+6.1%
CVS CVSG.LUnited Kingdom$1.22B+17%+6%11%14.6×14.2%+6.9%
Krishna Institute of Medical Sciences KIMS.NSIndia$3.41B+2%+35%11%81.9×n/an/a
Surgery Partners SGRYUnited States$3.53B+100%+2%13%77.2×15.6%+12.2%
Yatharth Hospital and Trauma Care Services YATHARTH.NSIndia$1.13B+31%+50%16%49.4×n/an/a
Park Medi World PARKHOSPS.NSIndia$1.10B-4%+21%21%30.6×22.1%+10.2%
Rhon-klinikum RHK.DEGermany$1.06B+15%+4%-51%22.5×n/an/a
Jupiter Life Line Hospitals JLHL.NSIndia$1.01B+9%+17%16%48.8×n/an/a
Clinica Baviera CBAV.MCSpain$1.01B+2%+11%20%20.1×2.3%+19.7%

Questions

Who are Ardent Health's main competitors?
Named competitors: HCA Healthcare (HCA), Community Health Systems (CYH), Tenet Healthcare (THC), Universal Health Services (UHS). The cockpit's measured peer set (industry) also includes Brookdale Senior Living (BKD), Extendicare (EXE.TO), Huaxia Eye Hospital (301267.SZ), Topchoice Medical (600763.SS), Sienna Senior Living (SIA.TO), Xi'an International Medical Investment (000516.SZ).
Is Ardent Health expensive compared with its peers?
On forward p/e it trades at 11.9× against a peer median of 35.5×, cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Ardent Health stock performed?
Over six months to 18 Nov 2026 the shares returned +52.4% against -0.6% for the median peer; over one year +73.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.